免疫联合方案治疗转移性肾细胞癌:随机临床试验荟萃分析
该荟萃分析纳入6项III期随机试验共5175例初治转移性肾细胞癌患者,比较免疫联合方案与舒尼替尼的疗效。结果显示免疫联合方案显著改善总生存(HR 0.74)、无进展生存(HR 0.68)、完全缓解率(OR 3.04)和客观缓解率(OR 2.53)。
要点
- 免疫联合方案较舒尼替尼降低26%死亡风险(HR 0.74,95%CI 0.67-0.81)。
- 免疫联合方案显著改善PFS(HR 0.68,95%CI 0.54-0.85)。
- 完全缓解率提高至三倍以上(OR 3.04,95%CI 2.31-3.99)。
核心结论
- 免疫联合方案在初治转移性肾细胞癌中较舒尼替尼显著改善OS、PFS、CR率和ORR。
研究设计与样本
- 荟萃分析纳入2008年6月15日至2021年2月24日发表的6项III期随机试验,共5175例初治mRCC患者(免疫联合组2576例,舒尼替尼组2597例)。
主要发现
- 免疫联合方案降低26%死亡风险(HR 0.74,95%CI 0.67-0.81,P<0.001)。
- 免疫联合方案改善PFS(HR 0.68,95%CI 0.54-0.85,P=0.001)。
- 免疫联合方案提高CR率(OR 3.04,95%CI 2.31-3.99,P=0.001)。
- 免疫联合方案提高ORR(OR 2.53,95%CI 1.77-3.62,P<0.03)。
临床怎么用
- 初治转移性肾细胞癌可优先考虑免疫联合方案以改善生存和缓解率。
局限性
- 需真实世界研究验证本荟萃分析结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent years have witnessed the advent of novel treatment options for metastatic renal cell carcinoma (mRCC), including combination therapies with immune checkpoint inhibitors. Herein, we conducted an up-to-date and comprehensive meta-analysis including recently published data of phase III clinical trials evaluating immune-based combinations in mRCC. METHODS: We retrieved all the relevant trials published from 15th June 2008 to 24th February 2021, evaluating immune-based combinations in treatment-naïve mRCC through PubMed/MEDLINE, Cochrane library, and EMBASE; additionally, proceedings of the main international oncological meetings were also searched for relevant abstracts. Outcomes of interest included overall survival (OS), progression-free survival (PFS), complete response (CR) rate, and overall response rate (ORR). Hazard ratios (HRs) and their 95% confidence intervals (CIs) for OS and PFS, and odds ratios (ORs) and 95% CIs for CR rate and ORR, were extracted. RESULTS: Overall, 6 phase III studies involving 5175 treatment-naïve mRCC patients were available for the meta-analysis (immune-based combinations, n = 2576; sunitinib, n = 2597). According to our results, the use of immune-based combinations decreased the risk of death by 26% (HR 0.74, 95% CI 0.67-0.81, P < 0.001); similarly, a PFS benefit was observed (HR 0.68, 95% CI 0.54-0.85, P = 0.001). In addition, immune-based combinations showed better CR rate and ORR, with ORs of 3.04 (95% CI 2.31-3.99, P = 0.001) and 2.53 (95% CI 1.77-3.62, P < 0.03), respectively. CONCLUSIONS: The results of our meta-analysis confirm the clinical benefit provided by immunotherapy combinations, with CR rate more than tripled in mRCCs receiving immune-based combinations. Further studies in real-world setting are warranted to validate the findings of our meta-analysis, the most updated to systematically evaluate immune-based combinations in mRCC.
引用
- Massari F, Rizzo A, Mollica V, et al. Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. Eur J Cancer. 2021. PMID: 34265504. doi:10.1016/j.ejca.2021.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。